Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Guggulu,Guduchi,Yashtimadhu
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study has demonstrated a strong trend that adjuvant therapy with Septilin and Bresol along with SOC, supports immunity and controls inflammation in COVID-19-positive patients and helps in the recovery of symptoms of 'post-COVID-19 illness'.
Product Name : Septilin
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 12, 2020
Lead Product(s) : Guggulu,Guduchi,Yashtimadhu
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable